Aridis Pharmaceuticals ARDS announced that the FDA has accepted the company’s proposal of a single confirmatory phase III AR-301-003 study of its proprietary monoclonal antibody candidate, AR-301, for ...
May reduce secondary shock in severe pneumonia, but have little to no effect on hospital-acquired infections. (HealthDay News) — Adjunct corticosteroids probably reduce short-term mortality in adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results